# Pasithea Therapeutics Corp.: financial statements, quarterly

KTTA · Nasdaq · CIK 1841330 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ktta.md) · [Financials](/companies/ktta/financials.md) · [Filings](/companies/ktta/filings.md) · [Insiders](/companies/ktta/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ktta/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1.6](/filings/0001213900-24-097496.md) | [3.4 d](/filings/0001013762-25-001646.md) | [1.7](/filings/0001213900-25-044281.md) | [2.4](/filings/0001213900-25-076557.md) | [1.6](/filings/0001213900-25-110093.md) | [1.5 d](/filings/0001213900-26-036434.md) | [1.7](/filings/0001213900-26-057837.md) | [2.1](/filings/0001213900-26-090146.md) | [1.4](/filings/0001213900-25-110093.md) | [2.7 d](/filings/0001213900-26-036434.md) | [2.9](/filings/0001213900-26-057837.md) | [3.7](/filings/0001213900-26-090146.md) |
| Selling, general and administrative | $m | [2.2](/filings/0001213900-23-086198.md) | [1.8 d](/filings/0001013762-25-001646.md) | [2.3](/filings/0001213900-24-042981.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(3.8)](/filings/0001213900-24-097496.md) | [(5.1) d](/filings/0001013762-25-001646.md) | [(4.0)](/filings/0001213900-25-044281.md) | [(3.9)](/filings/0001213900-25-076557.md) | [(3.0)](/filings/0001213900-25-110093.md) | [(3.3) d](/filings/0001213900-26-036434.md) | [(3.7)](/filings/0001213900-26-057837.md) | [(3.8)](/filings/0001213900-26-090146.md) | [(3.1)](/filings/0001213900-25-110093.md) | [(10.3) d](/filings/0001213900-26-036434.md) | [(4.9)](/filings/0001213900-26-057837.md) | [(5.7)](/filings/0001213900-26-090146.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(3.6)](/filings/0001213900-24-097496.md) | [(5.0) d](/filings/0001013762-25-001646.md) | [(3.9)](/filings/0001213900-25-110093.md) | [(3.9)](/filings/0001213900-25-110093.md) | [(3.0)](/filings/0001213900-25-110093.md) | [(3.2) d](/filings/0001213900-26-036434.md) | [(3.6)](/filings/0001213900-26-090146.md) | [(3.7)](/filings/0001213900-26-090146.md) | [(3.0)](/filings/0001213900-25-110093.md) | [(10.1) d](/filings/0001213900-26-036434.md) | [(2.9)](/filings/0001213900-26-090146.md) | [(5.3)](/filings/0001213900-26-090146.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001213900-23-086198.md) | not reported | [(3.70)](/filings/0001213900-25-044281.md) | [(3.71)](/filings/0001213900-25-076557.md) | [(2.87)](/filings/0001213900-25-110093.md) | not reported | [(1.61)](/filings/0001213900-26-057837.md) | [(0.66)](/filings/0001213900-26-090146.md) | [(0.41)](/filings/0001213900-25-110093.md) | not reported | [(0.12)](/filings/0001213900-26-057837.md) | [(0.16)](/filings/0001213900-26-090146.md) |
| Basic EPS | $ per share | [0.00](/filings/0001213900-23-086198.md) | not reported | [(3.70)](/filings/0001213900-25-044281.md) | [(3.71)](/filings/0001213900-25-076557.md) | [(2.87)](/filings/0001213900-25-110093.md) | not reported | [(1.61)](/filings/0001213900-26-057837.md) | [(0.66)](/filings/0001213900-26-090146.md) | [(0.41)](/filings/0001213900-25-110093.md) | not reported | [(0.12)](/filings/0001213900-26-057837.md) | [(0.16)](/filings/0001213900-26-090146.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [19.6](/filings/0001213900-23-086198.md) | [16.3](/filings/0001013762-25-001646.md) | [12.0](/filings/0001213900-24-042981.md) | [8.0](/filings/0001213900-24-068297.md) | [9.4](/filings/0001213900-25-110093.md) | [6.9](/filings/0001213900-26-036434.md) | [5.3](/filings/0001213900-26-057837.md) | [7.2](/filings/0001213900-26-090146.md) | [4.1](/filings/0001213900-25-110093.md) | [55.2](/filings/0001213900-26-090146.md) | [50.4](/filings/0001213900-26-057837.md) | [45.7](/filings/0001213900-26-090146.md) |
| Current assets | $m | [20.8](/filings/0001213900-23-086198.md) | [16.7](/filings/0001013762-25-001646.md) | [13.2](/filings/0001213900-24-042981.md) | [8.6](/filings/0001213900-24-068297.md) | [9.8](/filings/0001213900-24-097496.md) | [7.4](/filings/0001213900-26-036434.md) | [6.1](/filings/0001213900-25-044281.md) | [8.6](/filings/0001213900-25-076557.md) | [5.5](/filings/0001213900-25-110093.md) | [56.5](/filings/0001213900-26-090146.md) | [52.7](/filings/0001213900-26-057837.md) | [48.2](/filings/0001213900-26-090146.md) |
| Total assets | $m | [30.7](/filings/0001213900-23-086198.md) | [26.1](/filings/0001013762-25-001646.md) | [22.4](/filings/0001213900-24-042981.md) | [17.7](/filings/0001213900-24-068297.md) | [18.6](/filings/0001213900-24-097496.md) | [16.1](/filings/0001213900-26-036434.md) | [14.7](/filings/0001213900-25-044281.md) | [17.0](/filings/0001213900-25-076557.md) | [13.6](/filings/0001213900-25-110093.md) | [60.2](/filings/0001213900-26-090146.md) | [56.4](/filings/0001213900-26-057837.md) | [51.7](/filings/0001213900-26-090146.md) |
| Current liabilities | $m | [2.0](/filings/0001213900-23-086198.md) | [2.6](/filings/0001013762-25-001646.md) | [2.5](/filings/0001213900-24-042981.md) | [1.4](/filings/0001213900-24-068297.md) | [0.7](/filings/0001213900-24-097496.md) | [1.1](/filings/0001213900-26-036434.md) | [1.6](/filings/0001213900-25-044281.md) | [1.7](/filings/0001213900-25-076557.md) | [1.4](/filings/0001213900-25-110093.md) | [5.0](/filings/0001213900-26-090146.md) | [1.5](/filings/0001213900-26-057837.md) | [1.8](/filings/0001213900-26-090146.md) |
| Total liabilities | $m | [2.3](/filings/0001213900-23-086198.md) | [2.7](/filings/0001013762-25-001646.md) | [2.5](/filings/0001213900-24-042981.md) | [1.5](/filings/0001213900-24-068297.md) | [0.8](/filings/0001213900-24-097496.md) | [1.3](/filings/0001213900-26-036434.md) | [1.7](/filings/0001213900-25-044281.md) | [1.8](/filings/0001213900-25-076557.md) | [1.4](/filings/0001213900-25-110093.md) | [5.0](/filings/0001213900-26-090146.md) | [1.5](/filings/0001213900-26-057837.md) | [1.9](/filings/0001213900-26-090146.md) |
| Shareholders' equity | $m | [28.4](/filings/0001213900-24-097496.md) | [23.4](/filings/0001213900-26-036434.md) | [19.9](/filings/0001213900-25-110093.md) | [16.2](/filings/0001213900-25-110093.md) | [17.8](/filings/0001213900-25-110093.md) | [14.8](/filings/0001213900-26-090146.md) | [13.0](/filings/0001213900-26-090146.md) | [15.2](/filings/0001213900-26-090146.md) | [12.2](/filings/0001213900-25-110093.md) | [55.2](/filings/0001213900-26-090146.md) | [54.8](/filings/0001213900-26-090146.md) | [49.8](/filings/0001213900-26-090146.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,238) d](/filings/0001213900-24-097496.md) | [(3,294) d](/filings/0001013762-25-001646.md) | [(4,321)](/filings/0001213900-25-044281.md) | [(4,039) d](/filings/0001213900-25-076557.md) | [(3,120) d](/filings/0001213900-25-110093.md) | [(2,443) d](/filings/0001213900-26-036434.md) | [(3,056)](/filings/0001213900-26-057837.md) | [(3,869) d](/filings/0001213900-26-090146.md) | [(2,890) d](/filings/0001213900-25-110093.md) | [(5,397) d](/filings/0001213900-26-036434.md) | [(4,787)](/filings/0001213900-26-057837.md) | [(4,708) d](/filings/0001213900-26-090146.md) |
| Capital expenditure | $k | [(22.7) d](/filings/0001213900-24-097496.md) | [(0.0) d](/filings/0001013762-25-001646.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | [0.0 d](/filings/0001013762-25-001646.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations, us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [26.5](/filings/0001213900-23-086198.md) | [1.3](/filings/0001213900-24-042981.md) | [1.3](/filings/0001213900-24-068297.md) | [1.3](/filings/0001213900-24-097496.md) | [1.0](/filings/0001213900-25-044281.md) | [1.0](/filings/0001213900-25-076557.md) | [1.0](/filings/0001213900-25-110093.md) | [2.2](/filings/0001213900-26-057837.md) | [5.6](/filings/0001213900-26-090146.md) | [7.4](/filings/0001213900-25-110093.md) | [24.3](/filings/0001213900-26-057837.md) | [32.1](/filings/0001213900-26-090146.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 33,414,448 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-090146.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.